Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Tumor Angiogenesis Inhibition

Executive Summary: Anlotinib hydrochloride (CAS 1058157-76-8) is a potent, orally bioavailable multi-target tyrosine kinase inhibitor (TKI) that selectively inhibits VEGFR2 (IC₅₀: 5.6 ± 1.2 nM), PDGFRβ (8.7 ± 3.4 nM), and FGFR1 (11.7 ± 4.1 nM) [1]. The compound demonstrates superior anti-angiogenic activity compared to sunitinib, sorafenib, and nintedanib in both cell-based and in vivo assays. Anlotinib inhibits endothelial cell migration and capillary tube formation induced by VEGF, PDGF-BB, and FGF-2, and suppresses ERK pathway signaling [1]. Pharmacokinetic studies show high plasma protein binding (93% in humans), broad tissue distribution, and the ability to cross the blood-brain barrier [2]. Safety profiles indicate a high median lethal dose (LD₅₀: 1735.9 mg/kg, 14 days, oral, rat) with no significant organ or genetic toxicity at research doses [1].

Biological Rationale

Angiogenesis, the development of new blood vessels from existing vasculature, is crucial for tumor growth and metastasis [1]. Tumor cells secrete pro-angiogenic cytokines such as VEGF, PDGF-BB, and FGF-2 to stimulate endothelial cell migration and neovascularization. VEGF binds VEGFR2 on endothelial cells, triggering downstream signaling that promotes proliferation and migration. PDGF-BB and FGF-2 activate PDGFRβ and FGFR1, respectively, contributing to tumor angiogenesis [1]. Inhibiting these pathways is a validated strategy for halting tumor progression.

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib hydrochloride is a small-molecule TKI that targets multiple pro-angiogenic receptor tyrosine kinases:

• VEGFR2: Inhibits VEGF-induced phosphorylation and signaling (IC₅₀: 5.6 ± 1.2 nM).
• PDGFRβ: Blocks PDGF-BB-mediated activation (IC₅₀: 8.7 ± 3.4 nM).
• FGFR1: Suppresses FGF-2-induced autophosphorylation (IC₅₀: 11.7 ± 4.1 nM).
• ERK Signaling: Downstream inhibition reduces proliferation and migration [1].

This multi-target inhibition disrupts endothelial cell migration and capillary tube formation, key events in tumor neovascularization. The broad target profile distinguishes anlotinib from single-target TKIs and supports its utility in complex tumor models.

Evidence & Benchmarks

• Anlotinib shows nanomolar inhibitory potency: VEGFR2 (5.6 ± 1.2 nM), PDGFRβ (8.7 ± 3.4 nM), FGFR1 (11.7 ± 4.1 nM) (Lin et al. 2018, DOI).
• Demonstrates superior inhibition of endothelial cell migration and tube formation versus sunitinib, sorafenib, and nintedanib in EA.hy 926 cell assays (Lin et al. 2018, DOI).
• In vivo models (rat aortic ring, CAM assay) confirm suppression of microvessel density and blood vessel sprout formation (Lin et al. 2018, DOI).
• Pharmacokinetic data: oral bioavailability 28–58% (rat), 41–77% (dog); high plasma protein binding (93% in humans); large volume of distribution; crosses blood-brain barrier (APExBIO).
• Safety: LD₅₀ (oral, rat, 14 days) = 1735.9 mg/kg; no significant organ/genetic toxicity (Lin et al. 2018, DOI).

For a systems pharmacology overview, see this review, which complements this article by focusing on translational applications and clinical perspectives.

Applications, Limits & Misconceptions

Anlotinib hydrochloride is used in cancer research to dissect and inhibit angiogenic processes in preclinical models. It is suitable for:

• Cellular assays with human vascular endothelial cells (e.g., EA.hy 926) to study anti-angiogenic mechanisms.
• Migration and capillary tube formation assays (concentration-dependent effects).
• Signaling pathway modulation (VEGFR2, PDGFRβ, FGFR1, ERK).

Unlike agents that target single kinases, anlotinib addresses pathway redundancy often seen in tumor angiogenesis. For practical workflow considerations and troubleshooting, refer to this guide, which provides scenario-based solutions for lab assay challenges and how APExBIO's C8688 kit ensures reproducible research results. This article updates the mechanistic boundaries and application scope discussed in this summary by adding new pharmacokinetic and safety data.

Common Pitfalls or Misconceptions

• Not for clinical/therapeutic use: Anlotinib (hydrochloride) from APExBIO is strictly for scientific research; it is not approved for diagnostic or human therapeutic applications (APExBIO).
• Single pathway models: Efficacy may be underestimated if tested only against VEGF/VEGFR2 without considering PDGFRβ and FGFR1 signaling redundancy.
• Inappropriate storage: Compound must be stored at −20°C to maintain activity (APExBIO).
• Assay interference: High plasma protein binding may confound results in serum-rich media; controls are recommended.
• Species differences: Pharmacokinetic and toxicity data may not directly extrapolate from rodents/dogs to humans.

Workflow Integration & Parameters

Recommended Parameters:

• Storage: −20°C, desiccated; avoid repeated freeze–thaw cycles (APExBIO).
• Preparation: Dissolve in DMSO for stock solutions; dilute in assay buffer for final concentrations (typically 1–100 nM for cell-based studies).
• Controls: Include vehicle, sunitinib, sorafenib, and nintedanib for benchmarking.
• Assays: Wound healing, transwell migration, tube formation, and western blot for ERK pathway analysis.

For stepwise workflow integration and troubleshooting, see this protocol article, which this review extends by providing additional safety and PK/PD guidance.

Conclusion & Outlook

Anlotinib hydrochloride is a benchmark multi-target TKI for tumor angiogenesis research. Its nanomolar potency, high selectivity, and favorable pharmacokinetics make it a robust tool for dissecting VEGFR2, PDGFRβ, FGFR1, and ERK signaling in preclinical models. The compound, offered by APExBIO (C8688 kit), is strictly for research use. Ongoing studies may clarify translational boundaries and inform the design of next-generation anti-angiogenic agents.